Bioventus BVS U.S. Segment — Adjusted marketing expense

Similar metrics at other companies

OTEXReportable Segment — Adjusted marketing

$50.36M-1.1%

RMNIReportable Segment — Selling And Marketing Expense, Adjusted

$37.79M+13.4%

PCTYReportable Segment — Selling and Marketing Expense, Adjusted

$97.35M+5.0%

RELYReportable segment — Marketing and Advertising Expense, Adjusted

$15.24M-2.8%

FIVNReportable Segment — Adjusted Sales and Marketing Expense

$70.29M+9.9%

NETReportable Segment — Sales And Marketing Expense, Adjusted

$232.45M+27.6%

FAQ

What is Bioventus's U.S. segment — adjusted marketing expense?

Bioventus (BVS) reported U.S. segment — adjusted marketing expense of $6.05M in Q2 2026.

How has Bioventus's U.S. segment — adjusted marketing expense changed year-over-year?

Bioventus's U.S. segment — adjusted marketing expense decreased by 9.1% year-over-year, from $6.66M to $6.05M.

What is the long-term trend for Bioventus's U.S. segment — adjusted marketing expense?

Over 3 years (2022 to 2025), Bioventus's U.S. segment — adjusted marketing expense has grown at a -6.2% compound annual growth rate (CAGR), from $30.16M to $24.92M.

What does U.S. segment — adjusted marketing expense mean?

This metric tracks the adjusted expenditures dedicated to marketing campaigns, brand awareness, and product positioning within the U.S. segment. It provides insight into the company's strategy for capturing market share and supporting the commercial launch of new medical technologies.